Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: Post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1984-1988

  Kavanaugh, Arthur ^a   Puig, Lluis ^b   Gottlieb, Alice B ^c   Ritchlin, Christopher ^d   You, Yin ^e   Li, Shu ^e   Song, Michael ^e   Randazzo, Bruce ^e,f   Rahman, Proton ^g   McInnes, Iain B ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER   (United States)

^e JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

DMARDs (biologic); Psoriatic Arthritis; Spondyloarthritis

Indexed keywords

C REACTIVE PROTEIN; PLACEBO; USTEKINUMAB; DERMATOLOGICAL AGENT;

ADULT; ARTHRITIS; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DACTYLITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; INFECTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERIPHERAL ARTHRITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; SPONDYLITIS; TREATMENT DURATION; TREATMENT OUTCOME; ARTHRITIS, PSORIATIC; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; JOINT; PERIARTHRITIS; RADIOGRAPHY;

ADULT; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JOINTS; MALE; PERIARTHRITIS; RADIOGRAPHY; SPONDYLITIS; TREATMENT OUTCOME; USTEKINUMAB;

EID: 84964836426     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-209068     Document Type: Article

References (24)

1. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology (Oxford) 2015;54:20-8.
2. Maldonado Ficco H, Citera G, Maldonado Cocco JA. Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol 2014;33:243-6.
3. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1431-4.
4. Battistone MJ, Manaster BJ, Reda DJ, et al. The prevalence of sacroiliitis in psoriatic arthritis: new perspectives from a large, multicenter cohort. A Department of Veterans Affairs Cooperative Study. Skeletal Radiol 1999;28:196-201.
5. McInnes IB, Kavanaugh A, Gottlieb AB, et al., on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9.
6. Ritchlin C, Rahman P, Kavanaugh A, et al, on behalf of the PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-Tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
7. Kavanaugh A, Ritchlin C, Rahman P, et al, on behalf of the PSUMMIT-1 and 2 Study Groups. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis 2014;73:1000-6.
8. Lubrano E, Spadaro A, Marchesoni A, et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin Exp Rheumatol 2011;29:80-4.
9. Behrens F, Koehm M, Arndt U, et al. Does concomitant methotrexate with adalimumab influence treatment outcomes in patients with psoriatic arthritis? Data from a large observational study. J Rheumatol 2016;43:632-9.
10. Nash P, Lubrano E, Cauli A, et al. Updated guidelines for the management of axial disease in psoriatic arthritis. J Rheumatol 2014;41:2286-9.
11. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
12. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
13. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44.
14. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: A prospective study. J Rheumatol 2005;32:80-5.
15. Eder L, Chandran V, Shen H, et al. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010;69:2160-4.
16. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
17. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-A simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-16.
18. van der Heijde D, Landewé R, Klareskog L, et al. Presentation and analysis of data on radiographic outcome in clinical trials. Arthritis Rheum 2005;52:49-60.
19. Burton PR, Clayton DG, Cardon LR, et al., Wellcome Trust Case Control Consortium (WTCCC), The Australo-Anglo-American Spondylitis Consortium (TASC). Association scan of 14500 nsSNPs in four common diseases identifies variants involved in autoimmunity. Nat Genet 2007;39:1329-37.
20. Reveille JD, Sims AM, Danoy P, et al., The Australo-Anglo-American Spondylitis Consortium (TASC). Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123-7.
21. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in spondyloarthritis. Mol Immunol 2014;57:28-37.
22. Felson DT, Anderson JJ, Boers M, et al, American college of rheumatology: preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38, 727-35
23. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica, 1978, 157, 238-44
24. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al, Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis, 2003, 62, 127-32